Aug 15 (Reuters) - Lykos Therapeutics said on Thursday

it would reduce its workforce by 75% and initiate some executive

changes, days after the U.S. Food and Drug Administration

declined approval for its MDMA-based treatment for

post-traumatic stress disorder.

Lykos, formerly known as MAPS Public Benefit Corp, said its

founder Rick Doblin was leaving the company's board.

It said it was bringing in David Hough, former vice

president for research and development at Johnson & Johnson ( JNJ )

, to lead and oversee Lykos's clinical development

program.